FAPI-PET Opens a New Window for Understanding of Immune-Mediated Inflammatory Diseases

Torsten Kuwert, Christian Schmidkonz, Olaf Prante, Georg Schett, Andreas Ramming Abstract: In vivo visualization of inflammatory lesions in the body has been revolutionized by positron emission tomography (PET) with F-18-deoxyglucose (FDG) as a tracer and by magnetic resonance imaging (MRI) with gadolinium-labelled contrast media. Apart [...]

April 7th, 2022|Publications|

Comparison of 68 Ga-FAPI and 18 F-FDG PET/CT in the Evaluation of Advanced Lung Cancer

Lijuan Wang, Ganghua Tang, Kongzhen Hu, Xinran Liu, Wenlan Zhou, Hongsheng Li, Shun Huang, Yanjiang Han, Li Chen, Jinmei Zhong, Hubing WuAbstract:Background Gallium 68 (68Ga)-labeled fibroblast-activation protein inhibitor (FAPI) has recently been introduced as a promising tumor imaging agent. Purpose To compare 68Ga-FAPI PET/CT with fluorine [...]

April 1st, 2022|Publications|

Head-to-head Intra-individual Comparison of [ 68 Ga]-FAPI and [ 18 F]-FDG PET/CT in Patients with Bladder Cancer

E Novruzov, K Dendl, H Ndlovu, P L Choyke, M Dabir, M Beu, F Novruzov, E Mehdi, F Guliyev, S A Koerber, I Lawal, G Niegisch, J Debus, U Haberkorn, M Sathekge, F L Giesel Aim/purpose: Fibroblast activation protein-(FAP)-ligands, a novel class of tracers for [...]

March 29th, 2022|Publications|

Feasibility of [ 68 Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma

Lena M Unterrainer, Simon Lindner, Lennert Eismann, Jozefina Casuscelli, Franz-Josef Gildehaus, Vinh Ngoc Bui, Nathalie L Albert, Adrien Holzgreve, Leonie Beyer, Andrei Todica, Matthias Brendel, Clemens C Cyran, Alexander Karl, Christian G Stief, Stephan T Ledderose, Marcus Unterrainer, Peter Bartenstein, Vera Wenter, Alexander Kretschmer [...]

March 24th, 2022|Publications|

Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?

Chiara Da Pieve, Marta Costa Braga, David R Turton, Frank A Valla, Pinar Cakmak, Karl-Heinz Plate, Gabriela Kramer-Marek Abstract: Cancer-associated fibroblasts (CAFs) can strongly modulate the response to therapy of malignant tumor cells, facilitating their continuous proliferation and invading behaviors. In this context, several [...]

February 22nd, 2022|Publications|

New Fully Automated Preparation of High Apparent Molar Activity 68 Ga-FAPI-46 on a Trasis AiO Platform

Chiara Da Pieve, Marta Costa Braga, David R Turton, Frank A Valla, Pinar Cakmak, Karl-Heinz Plate, Gabriela Kramer-Marek Abstract:A large number of applications for fibroblast activation protein inhibitors (FAPI)-based PET agents have been evaluated in conditions ranging from cancer to non-malignant diseases such as [...]

January 20th, 2022|Publications|

Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review

Liang Zhao, Jianhao Chen, Yizhen Pang, Kaili Fu, Qihang Shang, Hua Wu, Long Sun, Qin Lin, Haojun Chen Abstract: In recent years, quinoline-based fibroblast activation protein (FAP) inhibitors (FAPI) have shown promising results in the diagnosis of cancer and several other diseases, making them [...]

January 9th, 2022|Publications|

FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?

Katharina Dendl 1,2 Stefan A. Koerber 3,4,5 Clemens Kratochwil 1 Jens Cardinale 1,2 Rebecca Finck 1 Mardjan Dabir 2 Emil Novruzov 2Tadashi Watabe 6 Vasko Kramer 7,8 Peter L. Choyke 9 Uwe Haberkorn 1,10,11 and Frederik L. Giesel 1,2 Abstract:A fibroblast activation protein (FAP) [...]

November 2nd, 2021|Publications|

New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress

Surachet Imlimthan, Euy Sung Moon, Hendrik Rathke, Ali Afshar-Oromieh, Frank Rösch, Axel Rominger, Eleni Gourni Abstract: Over the past decade, the tumor microenvironment (TME) has become a new paradigm of cancer diagnosis and therapy due to its unique biological features, mainly the interconnection between [...]

October 5th, 2021|Publications|

FAPI-74 PET/CT Using Either 18 F-AlF or Cold-Kit 68 Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients

Frederik L Giesel 1, Sebastian Adeberg 2 3 4 5, Mustafa Syed 2 4, Thomas Lindner 1, Luis David Jiménez-Franco 6, Eleni Mavriopoulou 1, Fabian Staudinger 1, Eric Tonndorf-Martini 2 4, Sebastian Regnery 2 4, Stefan Rieken 2 5 7, Rami El Shafie 2 5, Manuel Röhrich 1, Paul Flechsig 1, Andreas Kluge 6, Annette Altmann 1, Jürgen Debus 2 3 4 5, Uwe Haberkorn 8 9, Clemens Kratochwil 1 Abstract: 68Ga-fibroblast activation protein inhibitors (FAPIs) 2, 4, and 46 have already been proposed as promising PET tracers. However, the short half-life [...]

February 24th, 2021|Publications|


Are you a pharmaceutical company or distribution network interested obtaining FAPI for your projects and patients? We are eager to learn more about how our compounds can facilitate your needs.

Go to Top